Information on EC 3.4.17.23 - angiotensin-converting enzyme 2

Word Map on EC 3.4.17.23
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY hide
3.4.17.23
-
RECOMMENDED NAME
GeneOntology No.
angiotensin-converting enzyme 2
-
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
angiotensin II + H2O = angiotensin-(1-7) + L-phenylalanine
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hydrolysis of peptide bond
CAS REGISTRY NUMBER
COMMENTARY hide
328404-18-8
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
precursor; Felis silvestris catus, domestic cat
UniProt
Manually annotated by BRENDA team
Sprague-Dawley
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
metabolism
-
ACE2 ia a component of the renin-angiotensin system, RAS
physiological function
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(7-methoxycoumarin-4-yl)-acetyl-Ala-Pro-Lys(2,4-dinitrophenyl) + H2O
(7-methoxycoumarin-4-yl)-acetyl-Ala-Pro + N6-(2,4-dinitrophenyl)-L-Lys
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)-acetyl-APK(2,4-dinitrophenyl) + H2O
(7-methoxycoumarin-4-yl)-acetyl-AP + N6-(2,4-dinitrophenyl)-L-Lys
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)-acetyl-APK(2,4-dinitrophenyl)-OH + H2O
(7-methoxycoumarin-4-yl)-acetyl-AP + N6-(2,4-dinitrophenyl)-L-Lys
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH + H2O
(7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro + N6-(2,4-dinitrophenyl)-L-Lys
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)-acetyl-YVADAPK-(2,4-dinitrophenyl)-OH + H2O
(7-methoxycoumarin-4-yl)-acetyl-YVADAP + N6-(2,4-dinitrophenyl)-L-Lys
show the reaction diagram
(7-methoxycoumarin-4-yl)-YVADAPK-(2,4-dinitrophenyl)-OH + H2O
(7-methoxycoumarin-4-yl)-YVADAP + N6-(2,4-dinitrophenyl)-L-lysine
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)acetyl-Ala-Pro-Lys(2,4-dinitrophenyl) + H2O
(7-methoxycoumarin-4-yl)acetyl-Ala-Pro + N6-(2,4-dinitrophenyl)-L-lysine
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)acetyl-APK(2,4-dinitrophenyl) + H2O
(7-methoxycoumarin-4-yl)acetyl-AP + N6-(2,4-dinitrophenyl)-L-lysine
show the reaction diagram
(7-methoxycoumarin-4-yl)acetyl-APK(2,4-dinitrophenyl)-OH + H2O
(7-methoxycoumarin-4-yl)acetyl-AP + N6-(2,4-dinitrophenyl)-L-lysine
show the reaction diagram
-
synthetic fluorogenic substrate
-
-
-
(7-methoxycoumarin-4-yl)acetyl-APK-(2,4-dinitrophenyl)-OH + H2O
?
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)acetyl-APK-2,4-dinitrophenyl + H2O
(7-methoxycoumarin-4-yl)acetyl-AP + N6-(2,4-dinitrophenyl)-L-lysine
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)acetyl-YVADAPK(2,4-dinitrophenyl)-OH + H2O
(7-methoxycoumarin-4-yl)acetyl-YVADAP + N6-(2,4-dinitrophenyl)-L-lysine
show the reaction diagram
-
synthetic fluorogenic caspase-1 substrate
-
-
-
(des-Arg9)-bradykinin + H2O
?
show the reaction diagram
-
-
-
-
?
7-methoxycoumarin-4-acetyl-Ala-Pro-Lys-(2,4-dinitrophenyl)-OH + H2O
?
show the reaction diagram
-
-
-
-
?
7-methoxycoumarin-4-acetyl-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys-(2,4-dinitrophenyl)-OH + H2O
?
show the reaction diagram
7-methoxycoumarin-4-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys-(2,4-dinitrophenyl)-OH + H2O
?
show the reaction diagram
amyloid-beta protein 43 + H2O
amyloid-beta protein 42 + ?
show the reaction diagram
-
ACE2 converts amyloid-beta protein 43 to amyloid-beta protein 42 in mouse brain lysates
-
-
?
angiotensin I + H2O
angiotensin-(1-9) + Leu
show the reaction diagram
angiotensin II + H2O
angiotensin(1-7) + L-Phe
show the reaction diagram
angiotensin II + H2O
angiotensin-(1-7) + L-Phe
show the reaction diagram
angiotensin II + H2O
angiotensin-(1-7) + Phe
show the reaction diagram
angiotensin IV + H2O
VYIHP + Phe
show the reaction diagram
-
-
-
-
?
angiotensin-(3-8) + H2O
angiotensin-(3-7) + Phe
show the reaction diagram
-
-
-
-
ir
angiotensin-(4-8) + H2O
angiotensin-(4-7) + Phe
show the reaction diagram
-
-
-
-
ir
angiotensin-(5-8) + H2O
angiotensin-(5-7) + Phe
show the reaction diagram
-
-
-
-
ir
apelin-13 + H2O
?
show the reaction diagram
apelin-13 + H2O
apelin-12 + Phe
show the reaction diagram
-
-
-
-
-
apelin-13 + H2O
QRPRLSHKGPMP + Phe
show the reaction diagram
apelin-36 + H2O
?
show the reaction diagram
apelin-36 + H2O
apelin-35 + Phe
show the reaction diagram
beta-casomorphin + H2O
?
show the reaction diagram
beta-casomorphin + H2O
YPFVEP + Ile
show the reaction diagram
-
-
-
-
?
casomorphin + H2O
?
show the reaction diagram
-
-
-
-
?
des-Arg10-Lys-bradykinin + H2O
KRPPGFSP + Phe
show the reaction diagram
-
-
-
-
?
des-Arg9-bradykinin + H2O
?
show the reaction diagram
des-Arg9-bradykinin + H2O
bradykinin (1-7) + Phe
show the reaction diagram
-
-
-
-
?
des-Arg9-bradykinin + H2O
RPPGFSP + Phe
show the reaction diagram
-
-
-
-
?
dynorphin A + H2O
?
show the reaction diagram
dynorphin A 1-13 + H2O
dynorphin A 1-12 + Lys
show the reaction diagram
-
-
-
-
ir
dynorphin A(1-13) + H2O
YGGFLRRIRPKL + Lys
show the reaction diagram
-
-
-
-
?
ghrelin + H2O
?
show the reaction diagram
-
-
-
-
?
ghrelin + H2O
ghrelin minus C-terminal amino acid + arginine
show the reaction diagram
-
-
-
-
ir
kinetensin + H2O
?
show the reaction diagram
-
-
-
-
?
KRPPGSPF + H2O
KRPPGSP + Phe
show the reaction diagram
-
i.e. Lys-des-Arg-bradykinin
-
-
ir
Lys-des-Arg9 bradykinin + H2O
KRPPGFSP + Phe
show the reaction diagram
-
-
-
-
?
Lys-des-Arg9-bradykinin + H2O
?
show the reaction diagram
neocasomorphin + H2O
neocasomorphin minus C-terminal amino acid + isoleucine
show the reaction diagram
-
-
-
-
ir
neurotensin + H2O
?
show the reaction diagram
neurotensin 1-13 + H2O
?
show the reaction diagram
-
-
-
-
?
neurotensin(1-11) + H2O
pELYENKPRRP + Tyr
show the reaction diagram
-
-
-
-
-
neurotensin(1-8) + H2O
pELYENKP + Arg
show the reaction diagram
-
-
-
-
?
neurotensin-(1-8) + H2O
neurotensin-(1-7) + arginine
show the reaction diagram
-
-
-
-
ir
RPPGSPF + H2O
RPPGSP + Phe
show the reaction diagram
SARS-coronavirus S1 protein + H2O
?
show the reaction diagram
TBC5046 + H2O
o-aminobenzoic acid-des-Arg-bradykinin-(1-7) + 3-nitrophenylalanine
show the reaction diagram
synthetic fluorogenic peptide, i.e. des-Arg-bradykinin with N-terminal o-aminobenzoic acid and a 3-nitrophenylalanine instead of Phe at the C-terminus
-
-
ir
YPVEPFI + H2O
YPVEPF + Ile
show the reaction diagram
-
i.e. beta-casomorphin
-
-
ir
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
amyloid-beta protein 43 + H2O
amyloid-beta protein 42 + ?
show the reaction diagram
-
ACE2 converts amyloid-beta protein 43 to amyloid-beta protein 42 in mouse brain lysates
-
-
?
angiotensin I + H2O
angiotensin-(1-9) + Leu
show the reaction diagram
angiotensin II + H2O
angiotensin(1-7) + L-Phe
show the reaction diagram
angiotensin II + H2O
angiotensin-(1-7) + L-Phe
show the reaction diagram
-
the enzyme is involved in the renin angiotensin system
-
-
?
angiotensin II + H2O
angiotensin-(1-7) + Phe
show the reaction diagram
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
F-
-
enhances activity by about 10fold
Zinc
-
zinc carboxypeptidase
additional information
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2S)-3-(biphenyl-4-yl)-2-((3S)-2-mercapto-3-methylpentanamido)propanoic acid
-
-
(2S)-3-biphenyl-4-yl-2-[(2-methyl-2-sulfanylpropanoyl)amino]propanoic acid
-
-
(2S)-3-biphenyl-4-yl-2-[(2-sulfanylpropanoyl)amino]propanoic acid
-
-
(2S)-3-biphenyl-4-yl-2-[(sulfanylacetyl)amino]propanoic acid
-
-
(2S)-3-biphenyl-4-yl-2-[[(2R)-2-sulfanylbutanoyl]amino]propanoic acid
-
-
(2S)-3-biphenyl-4-yl-2-[[(2R)-3-methyl-2-sulfanylbutanoyl]amino]propanoic acid
-
-
(2S)-3-biphenyl-4-yl-2-[[(2R)-3-phenyl-2-sulfanylpropanoyl]amino]propanoic acid
-
-
(2S)-3-biphenyl-4-yl-2-[[(2S)-2-phenyl-2-sulfanylacetyl]amino]propanoic acid
-
-
(2S)-3-biphenyl-4-yl-2-[[(2S)-2-sulfanylhexanoyl]amino]propanoic acid
-
-
(2S)-3-biphenyl-4-yl-2-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]propanoic acid
-
-
(2S)-3-biphenyl-4-yl-2-[[cyclobutyl(sulfanyl)acetyl]amino]propanoic acid
-
-
(S)-3-(biphenyl-4-yl)-2-((2R,3R)-2-mercapto-3-methylpentanamido)propanoic acid
-
-
(S)-3-(biphenyl-4-yl)-2-((R)-2-cyclohexyl-2-mercaptoacetamido)propanoic acid
-
-
(S)-3-(biphenyl-4-yl)-2-((R)-2-cyclopentyl-2-mercaptoacetamido)propanoic acid
-
-
(S)-3-(biphenyl-4-yl)-2-((R)-2-mercapto-3-(naphthalen-2-yl)propanamido)propanoic acid
-
-
(S)-3-(biphenyl-4-yl)-2-((R)-2-mercapto-4,4-dimethylpentanamido)propanoic acid
-
-
(S)-3-(biphenyl-4-yl)-2-((R)-2-mercapto-4-methylpentanamido)propanoic acid
-
-
(S)-3-(biphenyl-4-yl)-2-((R)-2-mercapto-4-phenylbutanamido)propanoic acid
-
-
(S)-3-(biphenyl-4-yl)-2-((R)-3-cyclohexyl-2-mercaptopropanamido)propanoic acid
-
-
(S,S)-2-[1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-inidazol-4-yl]-ethylamino]-4-methylpentanoic acid
-
MLN-4760
(S,S)-2-{1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]-ethylamino}-4-methylpentanoic acid
-
i.e MLN-4760
1,3,8-trihydroxy-6-methylanthraquinone
-
1,3,8-trihydroxy-6-methylanthraquinone (emodin) blocks interaction between the SARS corona virus spike protein and its receptor angiotensin-converting enzyme 2, 94.12% inhibition at 0.05 mM
1,4-bis-(1-anthraquinonylamino)-anthraquinone
-
slight inhibition
1,8,dihydroxy-3-carboxyl-9,10-anthraquinone
-
1,8,dihydroxy-3-carboxyl-9,10-anthraquinone (rhein) exhibits slight inhibition
1N-08795
-
90% inhibition at 0.2 mM
1N-26923
-
93% inhibition at 0.2 mM
1N-27714
-
89% inhibition at 0.2 mM
1N-28616
-
93% inhibition at 0.2 mM
1S-90995
-
11% inhibition at 0.2 mM
1S-91206
-
75% inhibition at 0.2 mM
2-benzyl-3-(hydroxy-pyrrolidin-2-yl-phosphinoyl)-propionic acid
-
-
2-benzyl-3-[(1-benzyloxycarbonylamino-2-phenyl-ethyl)-hydroxy-phosphinoyl]-propionic acid
-
-
2-benzyl-3-[(1-benzyloxycarbonylamino-3-methyl-butyl)-hydroxy-phosphinoyl]-propionic acid
-
-
2-benzyl-3-[(1-benzyloxycarbonylamino-ethyl)-hydroxy-phosphinoyl]-propionic acid
-
-
2-methylphenyl-benzylsuccinic acid
-
-
2-[(2-carboxy-3-phenyl-propyl)-hydroxy-phosphinoyl]-pyrrolidine-1-carboxylic acid benzyl ester
-
-
2-[(2-carboxy-4-methyl-pentyl)-hydroxy-phosphinoyl]-pyrrolidine-1-carboxylic acid benzyl ester
-
-
2-[(2-carboxy-propyl)-hydroxy-phosphinoyl]-pyrrolidine-1-carboxylic acid benzyl ester
-
-
3,4-dimethylphenyl-benzylsuccinic acid
-
-
3,5-dichloro-benzylsuccinate
-
-
3,5-dimethylphenyl-benzylsuccinic acid
-
-
3-([1-[2-acetylamino-3-(1H-imidazol-4-yl)-propionylamino]-3-methyl-butyl]-hydroxy-phosphinoyl)-2-(3-phenyl-isoxazol-5-ylmethyl)-propionic acid
-
-
3-([1-[2-acetylamino-3-(1H-imidazol-4-yl)-propionylamino]-3-methyl-butyl]-hydroxy-phosphinoyl)-2-benzyl-propionic acid
-
-
3-([1-[2-acetylamino-3-(1H-imidazol-4-yl)-propionyl]-pyrrolidin-2-yl]-hydroxy-phosphinoyl)-2-(3-phenyl-isoxazol-5-ylmethyl)-propionic acid
-
-
3-([1-[2-acetylamino-3-(1H-imidazol-4-yl)-propionyl]-pyrrolidin-2-yl]-hydroxy-phosphinoyl)-2-benzyl-propionic acid
-
-
3-([1-[2-acetylamino-3-(4-hydroxy-phenyl)-propionyl]-pyrrolidin-2-yl]-hydroxy-phosphinoyl)-2-benzyl-propionic acid
-
-
3-methylphenyl-benzylsuccinic acid
-
-
3-[(1-amino-2-phenyl-ethyl)-hydroxy-phosphinoyl]-2-benzylpropionic acid
-
-
3-[(1-amino-3-methyl-butyl)-hydroxy-phosphinoyl]-2-benzylpropionic acid
-
-
3-[(1-amino-ethyl)-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
-
3-[[1-(2-acetylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
-
3-[[1-(2-acetylamino-3-phenyl-propionyl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
-
3-[[1-(2-acetylamino-4-methyl-pentanoyl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-(3-phenyl-isoxazol-5-ylmethyl)-propionic acid
-
-
3-[[1-(2-acetylamino-4-methyl-pentanoyl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
-
3-[[1-(2-acetylamino-4-methyl-pentanoylamino)-2-phenylethyl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
-
3-[[1-(2-acetylamino-6-amino-hexanoyl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
-
3-[[1-(2-acetylamino-propionyl)-pyrrolidin-2-yl]-hydroxyphosphinoyl]-2-benzyl-propionic acid
-
-
3S-95223
-
40% inhibition at 0.2 mM
4-acetylamino-5-[2-[(2-carboxy-3-phenyl-propyl)-hydroxyphosphinoyl]-pyrrolidin-1-yl]-5-oxo-pentanoic acid
-
-
4-methylphenyl-benzylsuccinic acid
-
-
4-nitrophenyl-benzylsuccinic acid
-
-
4S-14713
-
70% inhibition at 0.2 mM
4S-16659
-
76% inhibition at 0.2 mM
5,7-dihydroxyflavone
-
5,7-dihydroxyflavone (chrysin) is a weak inhibitor
5115980
-
1% inhibition at 0.2 mM
7490938
-
20% inhibition at 0.2 mM
7850455
-
20% inhibition at 0.2 mM
7857351
-
27% inhibition at 0.2 mM
7870029
-
11% inhibition at 0.2 mM
Ac-GDYSHCSPLRYYPWWKCTYPDPEGGG-NH2
-
strong inhibition, most potent inhibitory peptide, i.e. DX600
Ac-GDYSHCSPLRYYPWWPDPEGGG-NH2
-
i.e. DX600
angiotensin I
-
-
angiotensin II C-terminal analogs
-
screening of a library of angiotensin II C-terminal analogs identifies a number of tetrapeptides with increased ACE2 inhibition, and identifies residues critical to the binding of angiotensin II to the active site of ACE2
-
anthraquinone
-
slight inhibition
benzylsuccinate
-
essentially abolishes the formation of Ang(1-9) by ACE2
Benzylsuccinic acid
-
-
Cu2+
-
69% inhibition at 0.01 mM
cyclohexyl-benzylsuccinic acid
-
-
dicyclohexyl-benzylsuccinic acid
-
-
Ile-Pro-Pro
-
inhibits EC 3.4.15.1 at one-thousandth of the concentration needed to inhibit ACE2
Leu-Pro-Pro
-
inhibits EC 3.4.15.1 at one-thousandth of the concentration needed to inhibit ACE2
MLN 4760
MLN-4760
MLN4760
-
-
N-[(1S)-1-carboxy-3-methylbutyl]-3-(3,5-dichlorobenzyl)-L-histidine
-
enzyme-specific inhibitor
N-[(1S)-1-carboxy-3-methylbutyl]-3-(3,5-dichlorophenyl)-L-histidine
-
i.e. C16, a ACE2 specific inhibitor
phenylbenzylsuccinic acid
-
-
Pro-Phe
T0507-4963
-
41% inhibition at 0.2 mM
T0513-5544
-
4% inhibition at 0.2 mM
T0515-3007
-
13% inhibition at 0.2 mM
telmisartan
-
specific angiotensin II type 1 receptor blocker
Val-Pro-Pro
-
inhibits EC 3.4.15.1 at one-thousandth of the concentration needed to inhibit ACE2
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
8-[[2-(dimethylamino)ethyl]amino]-5-(hydroxymethyl)-9-oxo-9H-xanthen-2-yl 4-methylbenzenesulfonate
-
enhances ACE2 activity in a dose-dependent manner and causes considerable reductions in blood pressure and a striking reversal of cardiac and renal fibrosis in the spontaneously hypertensive rat model of hypertension
all-trans retinoic acid
-
-
D-glucose
-
incubation of cells in high D-glucose increases ACE2 activity
losartan
resorcinolnaphthalein
-
enhances ACE2 activity in a dose-dependent manner
additional information
-
no activation by PD123319, an angiotensin II type 2 antagonist
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.147
(7-methoxycoumarin-4-yl)acetyl-APK(2,4-dinitrophenyl)-OH
-
pH 6.5, room temperature
0.0091
angiotensin 3-8
-
pH 7.4, 37°C
0.0126
angiotensin 4-8
-
pH 7.4, 37°C
0.0245
angiotensin 5-8
-
pH 7.4, 37°C
0.0069 - 0.0868
angiotensin I
0.005 - 0.0586
angiotensin II
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
6840
(7-methoxycoumarin-4-yl)acetyl-APK(2,4-dinitrophenyl)-OH
Homo sapiens
-
pH 6.5, room temperature
162
angiotensin 3-8
Homo sapiens
-
pH 7.4, 37°C
84
angiotensin 4-8
Homo sapiens
-
pH 7.4, 37°C
1518
angiotensin 5-8
Homo sapiens
-
pH 7.4, 37°C
2 - 2.9
angiotensin I
12.8 - 1110
angiotensin II
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0000015
(2S)-3-(biphenyl-4-yl)-2-((3S)-2-mercapto-3-methylpentanamido)propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.0023
(2S)-3-biphenyl-4-yl-2-[(2-methyl-2-sulfanylpropanoyl)amino]propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.0000069
(2S)-3-biphenyl-4-yl-2-[(2-sulfanylpropanoyl)amino]propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.00032
(2S)-3-biphenyl-4-yl-2-[(sulfanylacetyl)amino]propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.0000014
(2S)-3-biphenyl-4-yl-2-[[(2R)-2-sulfanylbutanoyl]amino]propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.0000015
(2S)-3-biphenyl-4-yl-2-[[(2R)-3-methyl-2-sulfanylbutanoyl]amino]propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.000086
(2S)-3-biphenyl-4-yl-2-[[(2R)-3-phenyl-2-sulfanylpropanoyl]amino]propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.000084
(2S)-3-biphenyl-4-yl-2-[[(2S)-2-phenyl-2-sulfanylacetyl]amino]propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.0000018
(2S)-3-biphenyl-4-yl-2-[[(2S)-2-sulfanylhexanoyl]amino]propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.0014
(2S)-3-biphenyl-4-yl-2-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.0000024
(2S)-3-biphenyl-4-yl-2-[[cyclobutyl(sulfanyl)acetyl]amino]propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.0000016
(S)-3-(biphenyl-4-yl)-2-((2R,3R)-2-mercapto-3-methylpentanamido)propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.000065
(S)-3-(biphenyl-4-yl)-2-((R)-2-cyclohexyl-2-mercaptoacetamido)propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.0000018
(S)-3-(biphenyl-4-yl)-2-((R)-2-cyclopentyl-2-mercaptoacetamido)propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.00055
(S)-3-(biphenyl-4-yl)-2-((R)-2-mercapto-3-(naphthalen-2-yl)propanamido)propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.0000071
(S)-3-(biphenyl-4-yl)-2-((R)-2-mercapto-4,4-dimethylpentanamido)propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.0000014
(S)-3-(biphenyl-4-yl)-2-((R)-2-mercapto-4-methylpentanamido)propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.00086
(S)-3-(biphenyl-4-yl)-2-((R)-2-mercapto-4-phenylbutanamido)propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.00042
(S)-3-(biphenyl-4-yl)-2-((R)-3-cyclohexyl-2-mercaptopropanamido)propanoic acid
-
apparent value, in (7-methoxycoumarin-4-yl)-acetyl-Tyr-Val-Ala-Asp-Ala-Pro-Lys(2,4-dinitrophenyl)-OH as substrate in 0.001 mM Zn(OAc)2, 0.1 mM TCEP, 50 mM HEPES, 0.3 mM CHAPS, and 300 mM NaCl, at pH 7.5
0.000044
(S,S)-2-[1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-inidazol-4-yl]-ethylamino]-4-methylpentanoic acid
-
-
0.01
2-benzyl-3-(hydroxy-pyrrolidin-2-yl-phosphinoyl)-propionic acid
-
Ki above 0.01 mM
0.01
2-benzyl-3-[(1-benzyloxycarbonylamino-2-phenyl-ethyl)-hydroxy-phosphinoyl]-propionic acid
-
Ki above 0.01 mM
0.008
2-benzyl-3-[(1-benzyloxycarbonylamino-3-methyl-butyl)-hydroxy-phosphinoyl]-propionic acid
-
-
0.01
2-benzyl-3-[(1-benzyloxycarbonylamino-ethyl)-hydroxy-phosphinoyl]-propionic acid
-
Ki above 0.01 mM
0.0003
2-[(2-carboxy-3-phenyl-propyl)-hydroxy-phosphinoyl]-pyrrolidine-1-carboxylic acid benzyl ester
-
-
0.003
2-[(2-carboxy-4-methyl-pentyl)-hydroxy-phosphinoyl]-pyrrolidine-1-carboxylic acid benzyl ester
-
-
0.003
2-[(2-carboxy-propyl)-hydroxy-phosphinoyl]-pyrrolidine-1-carboxylic acid benzyl ester
-
-
0.00022
3-([1-[2-acetylamino-3-(1H-imidazol-4-yl)-propionylamino]-3-methyl-butyl]-hydroxy-phosphinoyl)-2-(3-phenyl-isoxazol-5-ylmethyl)-propionic acid
-
-
0.0008
3-([1-[2-acetylamino-3-(1H-imidazol-4-yl)-propionylamino]-3-methyl-butyl]-hydroxy-phosphinoyl)-2-benzyl-propionic acid
-
-
0.0000004
3-([1-[2-acetylamino-3-(1H-imidazol-4-yl)-propionyl]-pyrrolidin-2-yl]-hydroxy-phosphinoyl)-2-(3-phenyl-isoxazol-5-ylmethyl)-propionic acid
-
-
0.0000021
3-([1-[2-acetylamino-3-(1H-imidazol-4-yl)-propionyl]-pyrrolidin-2-yl]-hydroxy-phosphinoyl)-2-benzyl-propionic acid
-
-
0.0000052
3-([1-[2-acetylamino-3-(4-hydroxy-phenyl)-propionyl]-pyrrolidin-2-yl]-hydroxy-phosphinoyl)-2-benzyl-propionic acid
-
-
0.01
3-[(1-amino-2-phenyl-ethyl)-hydroxy-phosphinoyl]-2-benzylpropionic acid
-
Ki above 0.01 mM
0.01
3-[(1-amino-3-methyl-butyl)-hydroxy-phosphinoyl]-2-benzylpropionic acid
-
Ki above 0.01 mM
0.01
3-[(1-amino-ethyl)-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
Ki above 0.01 mM
0.00000035
3-[[1-(2-acetylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
-
0.0000052
3-[[1-(2-acetylamino-3-phenyl-propionyl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
-
0.00000125
3-[[1-(2-acetylamino-4-methyl-pentanoyl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-(3-phenyl-isoxazol-5-ylmethyl)-propionic acid
-
-
0.0000066
3-[[1-(2-acetylamino-4-methyl-pentanoyl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
-
0.00092
3-[[1-(2-acetylamino-4-methyl-pentanoylamino)-2-phenylethyl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
-
0.0000065
3-[[1-(2-acetylamino-6-amino-hexanoyl)-pyrrolidin-2-yl]-hydroxy-phosphinoyl]-2-benzyl-propionic acid
-
-
0.0000075
3-[[1-(2-acetylamino-propionyl)-pyrrolidin-2-yl]-hydroxyphosphinoyl]-2-benzyl-propionic acid
-
-
0.000007
4-acetylamino-5-[2-[(2-carboxy-3-phenyl-propyl)-hydroxyphosphinoyl]-pyrrolidin-1-yl]-5-oxo-pentanoic acid
-
-
0.0028
Ac-GDYSHCSPLRYYPWWKCTYPDPEGGG-NH2
-
pH 8.0, room temperature with substrate angiotensin I, pH 7.4, room temperature with substrate (7-methoxycoumarin-4-yl)acetyl-YVADAPK(2,4-dinitrophenyl)-OH
0.0022
angiotensin I
-
-
0.0000028
DX600
-
-
additional information
additional information
-
Ki values of peptides from constrained peptide libraries
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.2
1,3,8-trihydroxy-6-methylanthraquinone
Homo sapiens
-
-
0.096
1N-08795
Homo sapiens
-
-
0.134
1N-26923
Homo sapiens
-
-
0.116
1N-28616
Homo sapiens
-
-
0.08 - 4
1S-91206
Homo sapiens
-
-
0.179
4S-14713
Homo sapiens
-
-
0.062
4S-16659
Homo sapiens
-
-
0.005
Cu2+
Homo sapiens
-
-
0.00001
DX600
Homo sapiens
-
IC50: 10 nM
0.000003
MLN 4760
0.00000044
MLN-4760
Homo sapiens
-
i.e. (SS) 2-[(1)-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]ethylamino]-4-methyl-pentanoic acid, IC50: 0.44 nM
0.15
Pro-Phe
Homo sapiens
-
IC50: 0.15 mM
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
-
ACE2 activity shows a tendency to decrease in the serum of Alzheimer disease patients compared with normal controls
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
8
-
assay at
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
4.5 - 8
-
activity drops sharply at pH 8.0, substantial activity at pH 4.5-6.5, inactive at pH 9.0
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
22
-
room temperature, assay at
42
-
assay at
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
low ACE mRNA expression
Manually annotated by BRENDA team
-
chronic treatment with the AT1R antagonist almesartan induces a fivefold increase in ACE2 mRNA in the aorta which leads to a significant increase in aortic angiotensin(1-7) protein expression
Manually annotated by BRENDA team
-
non-diseased mammary arteries and atherosclerotic carotid arteries. Total vessel wall expression of ACE and ACE2 is similar during all stages of atherosclerosis. The observed ACE2 protein is enzymatically active and activity is lower in the stable advanced atherosclerotic lesions, compared to early and ruptured atherosclerotic lesions
Manually annotated by BRENDA team
-
ACE2 mRNA is expressed in early and advanced human carotid atherosclerotic lesions
Manually annotated by BRENDA team
-
low ACE mRNA expression
Manually annotated by BRENDA team
-
vascular walls and endothelium
Manually annotated by BRENDA team
-
expressed ACE2 to a high level, has not been shown to be infected by SARS-CoV. Presence of ACE2 alone is not sufficient for maintaining viral infection. Other virus receptors or coreceptors may be required in different tissues
Manually annotated by BRENDA team
-
surface enterocytes of the small intestine
Manually annotated by BRENDA team
-
vitreous body, retina and ciliary body. Counterbalancing interaction of ACE1 (EC 3.4.15.1) and ACE2 in physiological regulation of ocular circulation and pressure and possible protective role in certain ophthalmic disorders such as glaucoma and diabetic retinopathy
Manually annotated by BRENDA team
-
decreased ACE2 expression, expression profile in relation to clinicopathological factors, e.g. smoking, overview
Manually annotated by BRENDA team
-
ACE2 is shedded in mouse proximal tubular cells at positions 18-706 and 18-577, respectively
Manually annotated by BRENDA team
-
predominantly in proximal tubules, diabetic rats, 30% reduced enzyme content
Manually annotated by BRENDA team
-
low ACE mRNA expression
Manually annotated by BRENDA team
-
during pregnancy the placenta and the uterus, constitute important sources of ACE2, in addition to its normal production in the kidney, leading to an estimated twofold increase in total ACE2 activity
Manually annotated by BRENDA team
-
total vessel wall expression of ACE and ACE2 is similar during all stages of atherosclerosis. The observed ACE2 protein is enzymatically active and activity is lower in the stable advanced atherosclerotic lesions, compared to early and ruptured atherosclerotic lesions
Manually annotated by BRENDA team
additional information
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
additional information
-
transmembrane domain
-
Manually annotated by BRENDA team
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
27000
-
SDS-PAGE
42000
His-tagged ACE219-367, SDS-PAGE
70000
-
shedded ACE2 in proximal tubular cells
80000
-
SDS-PAGE
89600
-
recombinant enzyme, MALDI-TOF mass spectrometry
92000
-
SDS-PAGE
92460
-
DNA sequence determination
100000
-
mass spectroscopy, full-length
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
glycoprotein
proteolytic modification
-
ACE2 is is shed from human airway epithelia, constitutive generation of soluble ACE2 is inhibited by ADAM17 inhibitor DPC 333, i.e. (2R)-2-[(3R)-3-amino-3(4-[2-methyl-(4-quinolinyl) methoxy] phenyl)-2-oxopyrrolidinyl]-N-hydroxy-4-methylpentanamide, but not by while ADAM10 inhibitor GI254023, while phorbol ester, ionomycin, endotoxin, and IL-1beta and TNFalpha acutely induce ACE2 release, thus, the regulation of ACE2 cleavage involves a disintegrin and metalloprotease 17, ADAM17, and ADAM10, overview. The ACE2 ectodomain regulates its release and residue L584 might be part of a putative sheddase recognition motif
Crystallization/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
hanging drop vapor diffusion at 16-18°C, crystal structures of the native and inhibitor-bound forms of the ACE2 extracellular domains are solved to 2.2 A and 3.0 A resolution; hanging drop vapor diffusion at 16-18°C, crystal structures of the native and inhibitor(MLN-4760)-bound forms of the ACE2 extracellular domains are solved to 2.2 and 3.0 A resolution, respectively
-
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
22
-
recombinant enzyme, at room temperature, stable for 6 h
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
Zn2+ stabilizes
-
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
Ni3+-charged nitrilotriacetic acid-linked resin chromatography and and anti-Flag column chromatography
-
nickel-nitrilotriacetic acid agarose affinity chromatography
recombinant from CHO K1 cells
-
recombinant from Sf21 cells as mIgG-tagged protein
-
recombinant from Sf9 cells, to near homogeneity
-
recombinant wild-type and extracellular domain as FLAG-tagged proteins from Sf9 cells
-
recombinant; recombinant truncated extracellular form of human ACE2 (residues 1–740)
-
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
ACE2 expressed in Chinese hamster ovary cells specifically binds to glutathione-S-transferase-calmodulin, but not glutathione-S-transferase alone
-
ACE2 expression analysis
-
ACE2 expression analysis by RT-PCR
-
cloning and expression of a constitutively secreted form of ACE2, WKY rats are transduced with lentiviral vector containing shACE2. The plasma ACE2 levels could be increased by lentivector-mediated shACE2 gene transfer. This provides a tool to investigate the role of this enzyme in the development of the cardiovascular disease both through the role of hyperactivity of the RAS and through infectious agents
-
cloning of the enzyme utilizing the murine cytomegalovirus immediate early gene promoter, MCMV Pr, in an adenoviral vector for ACE2 overexpression in rats as a gene therapy model. overview
-
development of a transgenic mouse model (syn-hACE2) where the full open reading frame of the human ACE2 gene is under the control of a synapsin promoter, allowing the hACE2 protein to be expressed specifically in neurons
-
DNA and amino acid sequence determination, gene maps to choromosomal location Xp22, expression in CHO cells of the wild-type and of the soluble truncated mutant, the latter as c-Myc- and His-tagged protein
-
expressed in CHO cells
-
expressed in Escherichia coli BL21(DE3) cells
expressed in HEK 293-T cells
-
expressed in HEK-ACE2 cells
-
expressed in the endothelial cell line Eahy926
-
expression in CHO cells
-
expression in CHO cells and polarized Madin-Darby canine kidney epithelial cells
-
expression in E4 cells
-
expression in HEK-293 cells
-
expression in Spodoptera frugiperda Sf9 cells via infection with baculovirus
-
expression of extracellular domain and wild-type, both as FLAG-tagged proteins, in Spodotera frugiperda Sf9 cells via baculovirus infection
-
expression of recombinant ACE2 in P-selectin-transfected Chinese hamster ovary cells
expression of the mutant enzyme in CHO cells
-
expression of wild-type and utant L584A ACE2 in HEK-293 cells
-
gene ACE2, DNA sequence determination and analysis, expression in CHO K1 cells, secretion of the active enzyme from transfected cells by cleavage N-terminal to the transmembrane domain
-
overexpression of ACE2, by usage of a recombinant adeno-associated virus 6 delivery system, in myocardium of stroke-prone spontaneously hypertensive rats, gene expression profiling, overview
-
Sf21 cells via infection with baculovirus, mIgG-tagged protein
-
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
angiotensin II downregulates ACE2, but increases the expression of vascular endothelial growth factor and type receptor AT1-R, overview
-
angiotensin peptides modulate the expression of angiotensin converting enzyme II in the cardiovascular system, angiotensin II upregulates ACE2, modulated through activation of Ang II type 1 receptor, AT1R, and increases Ang-(1-7) formation from Ang II, and ACE2 expression is further enhanced by Ang-(1-7) in a positive feedback loop, molecular mechanism, overview. The upregulation is inhibited by Ang-(1-7) Mas receptor blockade through PD98059
-
central angiotensin II type 1 receptors reduce ACE2 expression/activity in hypertensive mice
-
elevated expression in kidney and heart in a rat model with chronic heart failure
-
high sucrose intake induces ACE2 expression in epididymal adipose tissue and kidney, leading to increased ACE2 and angiotensin-(1-7) levels in the adipose tissue
-
infection with highly pathogenic avian influenza A H5N1 virus results in downregulation of angiotensin-converting enzyme 2 (ACE2) expression in the lung
-
infection with highly pathogenic avian influenza A H5N1 virus results in increased expression of angiotensin-converting enzyme 2 (ACE2) in serum
-
mice infected with influenza H7N9 virus downregulate ACE2 protein markedly on day 3 after infection
-
miR-421 (miRNA) downregulates the expression of ACE2 in human cells by interacting with a specific sequence in its 3'-UTR and thereby repressing translation
-
the enzyme expression is upregulated in case of induced liver fibrosis and is further upregulated by additional administration of ACE I inhibitor peptide, pGlu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro, in hepatic stellate cells
-
up-regulated expression in patients with heart failure and hypertension
-
ENGINEERING
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
H345A
-
no activity with (7-methoxycoumarin-4-yl)acetyl-APK-2,4-dinitrophenyl
H345L
-
no activity with (7-methoxycoumarin-4-yl)acetyl-APK-2,4-dinitrophenyl
H505A
-
1.5% of wild-type activity with (7-methoxycoumarin-4-yl)acetyl-APK-2,4-dinitrophenyl as substrate
H505L
-
no activity with (7-methoxycoumarin-4-yl)acetyl-APK-2,4-dinitrophenyl
K481Q
-
angiotensin I cleavage activity is 21% of wild-type activity, angiotensin II cleavage activity is 71.8% of wild-type activity
L584A
-
the point mutation in the ACE2 ectodomain markedly attenuates shedding. The resultant ACE2-L584A mutant trafficks to the cell membrane and facilitates SARS-CoV entry into target cells
N580A
-
the mutation in the ectodomain has no effect on sACE2 release
P583A
-
the mutation in the ectodomain has no effect on sACE2 release
R169QK481QR514Q
-
angiotensin I cleavage activity is 53.2% of wild-type activity, angiotensin II cleavage activity is 203.4% of wild-type activity
R273K
-
no activity with (7-methoxycoumarin-4-yl)acetyl-APK-2,4-dinitrophenyl
R273Q
-
no activity with (7-methoxycoumarin-4-yl)acetyl-APK-2,4-dinitrophenyl
R582A
-
the mutation in the ectodomain has no effect on sACE2 release
V581A
-
the mutation in the ectodomain has no effect on sACE2 release
V604A
-
the mutation in the ectodomain has no effect on sACE2 release
W271A
-
angiotensin I cleavage activity is 5.3% of wild-type activity, angiotensin II cleavage activity is 0.9% of wild-type activity. Lacks any significant chloride sensitivity with the substrate angiotensin I
additional information
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
analysis
medicine
pharmacology